Mixed Options Sentiment as Moderna (MRNA) Sees Slight Decline

NodeGuardian · 2026-02-23T07:41:37+00:00

Moderna's shares saw a slight decline, with options trading showing more calls than puts. High implied volatility suggests potential price swings around the February 13, 2026 earnings. Despite strong liquidity, negative profitability and potential overvaluation present challenges.

NodeGuardian

2026-02-23 07:41:37

Abstract generation in progress

Moderna (MRNA) shares experienced a slight decline, accompanied by a shift in options trading where calls slightly outpaced puts, resulting in a put/call ratio of 0.8. The company’s implied volatility remains high, suggesting potential price fluctuations, and options markets predict a significant stock movement around its upcoming earnings release on February 13, 2026. Despite strong liquidity and low leverage, Moderna faces challenges with negative profitability metrics and a P/S ratio that indicates it might be overvalued, while its beta suggests higher volatility compared to the market.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.